What are the anatomical and clinical features of thymoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Anatomical and Clinical Features of Thymoma

Thymoma is a rare neoplasm of the thymus gland that originates from epithelial tissue, characterized by slow growth, local extension, and association with various paraneoplastic syndromes. 1

Anatomical Features

Location and Structure

  • Located in the anterior mediastinum (most common primary tumor of this region) 1, 2
  • Originates from thymic epithelial cells 1
  • Usually presents as a well-defined, encapsulated mass (65% of cases) or as an invasive tumor (35% of cases) 1
  • Typically grows slowly and spreads by local extension 1

Radiological Appearance

  • Most commonly appears as a rounded, soft-tissue mass in the anterior superior mediastinum 2
  • CT and MRI findings may include:
    • Variable size
    • Lobulated or irregular contours
    • Calcifications
    • Infiltration of surrounding fat
    • Lung infiltration
    • Great vessel invasion or encirclement 1

Clinical Features

Epidemiology

  • Incidence: approximately 0.15 per 100,000 person-years in the United States 1
  • More common than thymic carcinomas, which have an estimated annual incidence of 0.48 per million 1
  • 5-year survival rate: approximately 90% for thymomas vs. 60% for thymic carcinomas 1

Presentation

  • About 30% of patients are asymptomatic, with tumors discovered incidentally on routine chest imaging 3
  • Local symptoms may include:
    • Cough
    • Chest pain
    • Hoarseness
    • Dyspnea 3
  • Metastases at diagnosis are uncommon 1, 3
  • Metastases, when present, are usually confined to the pleura, pericardium, or diaphragm 1
  • Extrathoracic metastases are rare 1

Paraneoplastic Syndromes

  • Approximately 40% of patients with thymoma have one or more paraneoplastic syndromes 4
  • Most common associated condition is myasthenia gravis (30-65% of cases) 4, 5
  • Other associated conditions include:
    • Pure red cell aplasia
    • Hypogammaglobulinemia
    • Other autoimmune disorders 1, 4
  • Autoimmune disorders have been reported as the cause of death in 25% of thymoma patients, especially those with early-stage tumors 1

Classification and Staging

Histological Classification

  • WHO classification (1999) is widely used and includes:
    • Type A: Neoplastic oval or spindle-shaped epithelial cells without atypia or lymphocytes
    • Type AB: Type A features with foci of lymphocytes
    • Type B (1-3): Characterized by plump epithelial cells with increasing proportions of epithelial cells and atypia
    • Type C: Thymic carcinomas 1

Staging Systems

  • Masaoka-Koga staging system is most widely used 1, 6:
    • Stage I: Completely encapsulated tumor
    • Stage II: Microscopic or macroscopic invasion into thymic or surrounding fatty tissue
    • Stage III: Macroscopic invasion into neighboring organs
    • Stage IVA: Pleural or pericardial metastasis
    • Stage IVB: Lymphogenous or hematogenous metastasis 1

Prognostic Factors

Key Determinants of Prognosis

  • Complete surgical resection is the most significant prognostic factor 1, 6
  • Disease stage strongly correlates with prognosis 1:
    • 10-year overall survival: 84% for Stage I, 83% for Stage IIA, 70% for Stage III, 42-53% for Stage IV 1
    • 10-year cumulative incidence of recurrence: 8% for Stage IIA, 29% for Stage III, 57-71% for Stage IV 1
  • Histologic subtype has prognostic value but is less important than resection status and stage 6
  • Vascular invasion is a negative prognostic indicator 6

Clinical Pitfalls and Considerations

  • Thymomas have a tendency for late recurrence, even after complete resection, necessitating long-term follow-up 1
  • Up to 50-60% of patients do not die from progression of the thymic tumor but from other causes, including associated autoimmune disorders 1
  • The evolution of autoimmune disorders associated with thymoma does not parallel the progression of the tumor itself 1
  • Extrathymic malignancies develop in up to 20% of patients with thymoma 4
  • Distinguishing between thymoma and thymic carcinoma is crucial, as thymic carcinomas have markedly worse survival rates 1
  • The term "epithelial tumor of the thymus" is preferred over "thymoma" as it encompasses both thymomas and thymic carcinomas 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Thymoma: radiologic-pathologic correlation.

Radiographics : a review publication of the Radiological Society of North America, Inc, 1992

Research

When to suspect a thymoma: clinical point of view.

Journal of thoracic disease, 2020

Research

Thymoma.

Mayo Clinic proceedings, 1993

Guideline

Thymoma, Germ Cell Tumor, and Lymphoma Prognosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.